The MAF Test® is now available to oncologists and pathologists in Sub-Saharan Africa and will benefit an estimated 10,200 new patients each year just in South Africa.

SPA Farma, a leading pharmaceutical company of innovative healthcare products and diagnostic tools, and Inbiomotion, proprietors of MAF Test® for identifying high risk early-stage breast cancer ...

The MAF Test allows the identification of breast cancer patients with a greater risk of developing metastasis and facilitates informed decisions by oncologists about the most appropriate treatment ...